Literature DB >> 23924642

Rilpivirine resistance-associated mutations among antiretroviral-naive patients infected with HIV-1 in Asia.

Somnuek Sungkanuparph, Awachana Jiamsakul, Sasisopin Kiertiburanakul, Sunee Sirivichayakul, Jutarat Praparattanapan, Rami Kantor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23924642      PMCID： PMC3738917          DOI： 10.1097/QAI.0b013e31827a34b2

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  15 in total

Review 1.  Scale-up of national antiretroviral therapy programs: progress and challenges in the Asia Pacific region.

Authors:  Padmini Srikantiah; Massimo Ghidinelli; Damodar Bachani; Sanchai Chasombat; Esorom Daoni; Dyah E Mustikawati; Do T Nhan; Laxmi R Pathak; Khin O San; Mean C Vun; Fujie Zhang; Ying-Ru Lo; Jai P Narain
Journal:  AIDS       Date:  2010-09       Impact factor: 4.177

2.  FDA notifications. Complera approved.

Authors: 
Journal:  AIDS Alert       Date:  2011-11

Review 3.  2011 update of the drug resistance mutations in HIV-1.

Authors:  Victoria A Johnson; Vincent Calvez; Huldrych F Günthard; Roger Paredes; Deenan Pillay; Robert Shafer; Annemarie M Wensing; Douglas D Richman
Journal:  Top Antivir Med       Date:  2011-11

4.  Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.

Authors:  Laurence Rimsky; Johan Vingerhoets; Veerle Van Eygen; Joseph Eron; Bonaventura Clotet; Annemie Hoogstoel; Katia Boven; Gaston Picchio
Journal:  J Acquir Immune Defic Syndr       Date:  2012-01-01       Impact factor: 3.731

5.  Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

Authors:  Jean-Michel Molina; Pedro Cahn; Beatriz Grinsztejn; Adriano Lazzarin; Anthony Mills; Michael Saag; Khuanchai Supparatpinyo; Sharon Walmsley; Herta Crauwels; Laurence T Rimsky; Simon Vanveggel; Katia Boven
Journal:  Lancet       Date:  2011-07-16       Impact factor: 79.321

6.  Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.

Authors:  Calvin J Cohen; Jaime Andrade-Villanueva; Bonaventura Clotet; Jan Fourie; Margaret A Johnson; Kiat Ruxrungtham; Hao Wu; Carmen Zorrilla; Herta Crauwels; Laurence T Rimsky; Simon Vanveggel; Katia Boven
Journal:  Lancet       Date:  2011-07-16       Impact factor: 79.321

7.  Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.

Authors:  C Balotta; A Berlusconi; A Pan; M Violin; C Riva; M C Colombo; A Gori; L Papagno; S Corvasce; R Mazzucchelli; G Facchi; R Velleca; G Saporetti; M Galli; S Rusconi; M Moroni
Journal:  Antivir Ther       Date:  2000-03

Review 8.  Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.

Authors:  Jonathan Z Li; Roger Paredes; Heather J Ribaudo; Evguenia S Svarovskaia; Karin J Metzner; Michael J Kozal; Kathy Huppler Hullsiek; Melanie Balduin; Martin R Jakobsen; Anna Maria Geretti; Rodolphe Thiebaut; Lars Ostergaard; Bernard Masquelier; Jeffrey A Johnson; Michael D Miller; Daniel R Kuritzkes
Journal:  JAMA       Date:  2011-04-06       Impact factor: 56.272

9.  Antiretroviral therapy in AIDS patients with CMV disease: impact on the survival and long-term treatment outcome.

Authors:  Somnuek Sungkanuparph; Taywin Chakriyanuyok; Bodin Butthum
Journal:  J Infect       Date:  2007-11-26       Impact factor: 6.072

10.  Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific.

Authors:  Raph L Hamers; Rebecca Oyomopito; Cissy Kityo; Praphan Phanuphak; Margaret Siwale; Somnuek Sungkanuparph; Francesca Conradie; Nagalingeswaran Kumarasamy; Mariette E Botes; Thira Sirisanthana; Saade Abdallah; Patrick C K Li; Nicoletta Ngorima; Pacharee Kantipong; Akin Osibogun; Christopher K C Lee; Wendy S Stevens; Adeeba Kamarulzaman; Inge Derdelinckx; Yi-Ming Arthur Chen; Rob Schuurman; Michèle van Vugt; Tobias F Rinke de Wit
Journal:  Int J Epidemiol       Date:  2010-11-10       Impact factor: 7.196
View more
  2 in total

1.  Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries.

Authors:  Ujjwal Neogi; Amanda Häggblom; Kamalendra Singh; Leonard C Rogers; Shwetha D Rao; Wondwossen Amogne; Eugen Schülter; Maurizio Zazzi; Eddy Arnold; Stefan G Sarafianos; Anders Sönnerborg
Journal:  J Antimicrob Chemother       Date:  2015-10-30       Impact factor: 5.790

2.  Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.

Authors:  Kristof Theys; Kristel Van Laethem; Perpetua Gomes; Guy Baele; Andrea-Clemencia Pineda-Peña; Anne-Mieke Vandamme; Ricardo J Camacho; Ana B Abecasis
Journal:  AIDS Res Hum Retroviruses       Date:  2016-01-29       Impact factor: 2.205
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.